DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 23.53 percent increase over losses of $(0.17) per share from the same period last year.
Regions Financial Tops Q2 Revenue Estimate, EPS In-Line, Posts Substantial Credit Losses
Regions Financial Corp (NYSE: RF) clocked revenue growth of 12% Y/Y in Q2 FY23 to $1.957 billion,
